文献速递食管胃疾病与幽门螺杆菌消化内镜

转化型药代动力学/药效学方法支持伏诺拉生治疗糜烂性食管炎和幽门螺杆菌感染的最佳给药方案

A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-17

该研究汇总五项1期研究共245名参与者的胃内pH数据,建立药代动力学/药效学模型,模拟伏诺拉生20毫克每日一次和每日两次给药后pH>4和pH>6的保持时间比。结果显示两种给药方案均能实现高且剂量依赖的24小时胃酸抑制,支持其在酸相关疾病中的临床疗效数据。

要点

  • 伏诺拉生20毫克每日一次和每日两次均呈现高且剂量依赖的24小时胃内酸控制。
  • 模拟预测每日两次给药pH>6保持时间比达75.3%,高于每日一次的53.1%。
  • 该药代动力学/药效学模型结果支持伏诺拉生在酸相关疾病患者中的临床疗效数据。

核心结论

  • 伏诺拉生20毫克每日一次和每日两次给药在该药代动力学/药效学模型中表现出高且剂量依赖的24小时胃内酸控制,支持其在酸相关疾病患者中的临床疗效数据。

研究设计与样本

  • 汇总五项1期研究中有胃内pH测量数据的研究参与者,使用现有群体药代动力学模型预测药代动力学特征,建立三种直接连接药代动力学/药效学模型。
  • 共纳入245名参与者,其中95.1%为男性,50.6%为日本人,49.4%为非亚洲人。

主要发现

  • 给药前,平均pH>4保持时间比为6.4%,pH>5为3.2%,pH>6为1.2%。
  • 给药7天后,模拟预测伏诺拉生20毫克每日一次和每日两次的pH>4保持时间比分别为89.7%和98.1%。
  • 给药7天后,模拟预测伏诺拉生20毫克每日一次和每日两次的pH>6保持时间比分别为53.1%和75.3%。

关键数值与推荐

  • pH>4保持时间比对于糜烂性食管炎愈合重要,pH>6保持时间比对于幽门螺杆菌感染根除关键。
  • 伏诺拉生是一种在美国和其他国家获批的钾竞争性酸阻断剂,能可预测、快速且持续地抑制胃酸分泌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of acid-related disorders relies on gastric acid suppression. The percentage of time intragastric pH is >4 (pH >4 holding time ratio [HTR]) is important for healing erosive oesophagitis; and the pH >6 HTR is critical for eradication of Helicobacter pylori infection, as bacterial replication is active and antibiotic effectiveness is optimised. Vonoprazan, a potassium-competitive acid blocker approved in the USA and other countries, suppresses gastric acid secretion in a predictable, rapid and consistent manner, extended over prolonged periods. AIM: To explore the relationship between vonoprazan exposure and pH HTR through a pharmacokinetic/pharmacodynamic (PK/PD) model. METHODS: We pooled data from Phase 1 studies with intragastric pH measurements. Pharmacokinetic profiles were predicted for study participants using an existing population pharmacokinetic model. Pharmacokinetic and pharmacodynamic data were merged, and three direct-link PK/PD models were derived and used to simulate pH HTRs with between-participant variability for pH >4, >5 and >6, for vonoprazan doses of 20 mg once and twice daily. RESULTS: We used data from five Phase 1 studies to derive the PK/PD model. These included 245 participants (95.1% male, 50.6% Japanese and 49.4% non-Asian). Pre-dose, the mean pH >4 HTR was 6.4%, pH >5 3.2% and pH >6 1.2%. After 7 days of dosing, simulations predicted pH >4 HTRs of 89.7% and 98.1%, and pH >6 HTRs of 53.1% and 75.3%, for vonoprazan 20 mg once and twice daily, respectively. CONCLUSIONS: Vonoprazan 20 mg once- and twice-daily dosing demonstrated high, dose-dependent, 24-hour intragastric acid control in this PK/PD model, supporting clinical efficacy data in patients with acid-related disorders.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Scarpignato C, Howden CW, Leifke E, et al. A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Aliment Pharmacol Ther. 2023. PMID: 37066678. doi:10.1111/apt.17510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。